Targeted therapies: Afatinib-new therapy option for EGFR-mutant lung cancer

Nature Reviews Clinical Oncology

Volumn 10, Issue 10, 2013, Pages 551-552

  Yu, Helena A ^a   Pao, William ^b  

^a Thoracic Oncology Service   (United States)

^b VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFATINIB; ANTINEOPLASTIC AGENT; CETUXIMAB; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; GEMCITABINE; PEMETREXED; PLACEBO; PLATINUM COMPLEX; PROTEIN TYROSINE KINASE INHIBITOR;

CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; COUGHING; DIARRHEA; DOSE RESPONSE; DRUG APPROVAL; DRUG COST; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDICATION; DRUG POTENCY; DRUG SAFETY; DRUG WITHDRAWAL; DRY SKIN; DYSPHAGIA; DYSPNEA; EGFR GENE; EXON; FATIGUE; GENE DELETION; HUMAN; LARGE CELL CARCINOMA; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; METASTASIS; MOUTH PAIN; MUCOSA INFLAMMATION; NAIL; NAUSEA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RASH; SHORT SURVEY; SIDE EFFECT; SUBSTITUTION REACTION; TREATMENT PLANNING; UNSPECIFIED SIDE EFFECT;

CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; MOLECULAR TARGETED THERAPY; MUTATION; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84885022898     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2013.154     Document Type: Short Survey

References (10)

1. Pao, W. & Chmielecki, J. Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat. Rev. Cancer 10, 760-774 (2010).
2. Shepherd, F. A. et al. Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med. 353, 123-132 (2005). (Pubitemid 41058344)
3. Zhou, C. et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 12, 735-742 (2011).
4. Rosell, R. et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 13, 239-246 (2012).
5. Yu, H. et al. Analysis of mechanisms of acquired resistance to EGFR TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin. Cancer Res. 19, 2240-2247 (2013).
6. Sequist, L. V. et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J. Clin. Oncol. http://dx.doi.org/10.1200/JCO.2012.44.2806.
7. Yang, J. C. et al. Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations. J. Clin. Oncol. http://dx.doi.org/10. 1200/JCO.2012.46.1764.
8. Katakami, N. et al. LUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both. J. Clin. Oncol. http://dx.doi.org/10.1200/ JCO.2012.45.0981.
9. Miller, V. A. et al. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol. 13, 528-538 (2012).
10. Janjigian, Y. Y. et al. Activity of afatinib/cetuximab in patients (pts) with EGFR mutant non-small cell lung cancer (NSCLC) and acquired resistance (AR) to EGFR inhibitors [abstract]. Ann. Oncol. 23 (Suppl. 9), a12270 (2012).